Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. uri icon

authors

  • Ishola, David
  • Lowe, Brett
  • Kowuor, Dickens
  • Baiden, Frank
  • Mooney, Thomas
  • Smout, Elizabeth
  • Köhn, Brian
  • Otieno, Godfrey T
  • Jusu, Morrison
  • Foster, Julie
  • Samai, Mohamed
  • Manno, Daniela
  • Deen, Gibrilla Fadlu
  • Larson, Heidi
  • Lees, Shelley
  • Goldstein, Neil
  • Gallagher, Katherine E
  • Gaddah, Auguste
  • Heerwegh, Dirk
  • Callendret, Benoit
  • Luhn, Kerstin
  • Robinson, Cynthia
  • Afolabi, Muhammed O
  • Leyssen, Maarten
  • Greenwood, Brian
  • Douoguih, Macaya
  • Leigh, Bailah
  • Watson-Jones, Deborah
  • Keshinro, Babajide
  • Bockstal, Viki
  • Rogers, Baimba
  • Owusu-Kyei, Kwabena
  • Serry-Bangura, Alimamy
  • Swaray, Ibrahim

publication date

  • January 1, 2021